We are grateful for support from the U.S. National Institutes of Health.
NIGMS R01 GM067761: "Functional Genomic analysis using RNAi screen in Drosophila"
(N. Perrimon, PI; S. Mohr, Co-Investigator)(05/01/2003 - 11/30/2019)
NIGMS R01 GM084947: "Drosophila Transgenic RNAi Resource Project"
(N. Perrimon, PI)(09/01/2008 - 07/31/2020)
Office of the Director R24 OD021997: "Drosophila resources for modeling human diseases"
(N. Perrimon, PI)(06/01/2016 - 04/30/2020)
Office of the Director R24 OD019847: "Next-generation Drosophila cell lines to elucidate the cellular basis of human diseases" (N. Perrimon, PI; A. Simcox, Co-PI) (09/18/2017 - 08/31/2021)
Office of the Director R24 OD26435: "Using CRISPR technology to study the function of paralogous genes" (N. Perrimon, PI; H. Bellen, Co-PI; S. Mohr, Co-Investigator) (07/01/2018 - 6/30/2022)
We receive additional support via our participation in the Dana Farber/Harvard Cancer Center Collaborative Functional Genomics Core, which is supported by a grant to L. Glimcher (PI) from the NIH National Cancer Institute.
We are also grateful for equipment and related support from the Harvard Medical School Tools and Technologies program. HMS-TnT has made it possible for us to purchase and upgrade key equipment, as well as launch new innovative technologies.
An additional project ongoing at our group is the FlyBi project, which is supported by NIH-NHGRI (5R01HG007118; N. Perrimon, PI; M. Vidal, Co-Investigator; S. Celniker, Co-Investigator; S. Mohr, Project Manager).
In collaboration with the Gene Disruption Project we are using CRISPR to introduce swappable insertion cassettes into genes (NIH 5R01GM067858; H. Bellen, PI).
Prof. Perrimon is an Investigator of the Howard Hughes Medical Institute.
Recent past funding includes:
NCRR/ORIP R24 RR032668: "Development of validated Drosophila in vivo RNAi models of human diseases" (N. Perrimon, PI)(09/01/2011 - 07/31/2016)